Acrivon Therapeutics’ (ACRV) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research report released on Wednesday morning,Benzinga reports.

Several other brokerages have also weighed in on ACRV. KeyCorp began coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating for the company. HC Wainwright dropped their price target on shares of Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics has a consensus rating of “Buy” and a consensus price target of $23.17.

Acrivon Therapeutics Trading Down 11.1 %

Acrivon Therapeutics stock opened at $2.24 on Wednesday. Acrivon Therapeutics has a 52 week low of $2.14 and a 52 week high of $11.90. The stock has a market cap of $69.74 million, a price-to-earnings ratio of -0.83 and a beta of 0.85. The company’s 50-day moving average price is $5.35 and its two-hundred day moving average price is $6.53.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.06. Research analysts expect that Acrivon Therapeutics will post -2.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Acrivon Therapeutics

Several hedge funds have recently modified their holdings of ACRV. Wealthedge Investment Advisors LLC acquired a new stake in shares of Acrivon Therapeutics during the fourth quarter valued at approximately $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Acrivon Therapeutics by 29.7% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after purchasing an additional 23,535 shares in the last quarter. Corton Capital Inc. acquired a new stake in Acrivon Therapeutics during the 4th quarter valued at $73,000. Acorn Capital Advisors LLC purchased a new stake in shares of Acrivon Therapeutics in the fourth quarter valued at $2,440,000. Finally, Northern Trust Corp boosted its position in shares of Acrivon Therapeutics by 11.3% in the fourth quarter. Northern Trust Corp now owns 117,323 shares of the company’s stock worth $706,000 after buying an additional 11,925 shares during the period. 71.62% of the stock is owned by hedge funds and other institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.